Lipid-Lowering Agents - Lesotho

Lesotho

The revenue of the Lipid-Lowering Agents market in Lesotho is projected to reach US$152.60k in 2024.
It is expected to show an annual growth rate of 0.26% from 2024 to 2029, resulting in a market volume of US$154.60k by 2029.
In global comparison, United States is expected to generate the highest revenue of US$4,461.00m in 2024.
Lesotho's market for lipid-lowering agents is experiencing a growing demand for affordable generic options.

Key regions: Europe, Brazil, France, Australia, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

Lesotho, a small landlocked country surrounded by South Africa, has been experiencing a growing demand for Lipid-Lowering Agents in recent years.

Customer preferences: The increasing prevalence of obesity and related diseases such as diabetes and hypertension has led to a rising demand for Lipid-Lowering Agents in Lesotho. Customers in Lesotho are becoming more health-conscious and are seeking out medications that can help them manage their cholesterol levels.

Trends in the market: The Lipid-Lowering Agents market in Lesotho has been experiencing steady growth in recent years. This growth can be attributed to the increasing prevalence of lifestyle-related diseases, such as obesity and diabetes, which are major risk factors for cardiovascular diseases. The market is dominated by statins, which are the most commonly prescribed Lipid-Lowering Agents in the country. However, there has been a growing demand for newer and more effective drugs such as PCSK9 inhibitors, which have been shown to be effective in reducing cholesterol levels.

Local special circumstances: Lesotho has a high prevalence of HIV/AIDS, which has resulted in a large number of people taking antiretroviral therapy (ART). Some ART drugs have been known to cause dyslipidemia, which is a major risk factor for cardiovascular diseases. As a result, there has been a growing demand for Lipid-Lowering Agents among HIV-positive patients in Lesotho.

Underlying macroeconomic factors: Lesotho has a small and relatively undeveloped pharmaceutical market, with most drugs being imported from South Africa. The country has a low GDP per capita and a high poverty rate, which limits the affordability of Lipid-Lowering Agents for many people. The Lesotho government has implemented a number of policies to improve access to healthcare, including the introduction of a National Health Insurance Scheme in 2018. However, the scheme is still in its early stages and its impact on the Lipid-Lowering Agents market is yet to be seen.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.